Home » Topics » Disease categories and therapies » Urology

Urology
RSS

Pfizer begins first-in-human study of PF-06730512

June 7, 2017

Palladio Biosciences acquires rights to lixivaptan

May 24, 2017

EMA grants orphan drug designation to avacopan for C3 glomerulopathy

May 24, 2017

Otsuka reports topline results from phase III study of tolvaptan in ADPKD

May 23, 2017

Aurinia initiates phase III study of voclosporin for lupus nephritis

May 18, 2017

Omeros provides update on phase II study of OMS-721

May 18, 2017

FDA grants breakthrough therapy designation to vonapanitase from Proteon Therapeutics

May 11, 2017

Nymox seeks approval of fexapotide triflutate for BPH in five European countries

May 4, 2017

Aurinia outlines phase III plans for voclosporin in lupus nephritis

April 7, 2017

Sentien Biotechnologies closes series A financing to fund development of SBI-101

April 6, 2017

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
Sangamo presents primate data for prion suppressor ST-506
BioWorld Science
Sangamo Therapeutics Inc. discussed gene regulation approaches for neurodegenerative diseases when presenting findings on their clinical candidate ST-506 for the...
TREM2 agonists detailed in Pfizer patent
BioWorld Science
Pfizer Inc. has reported new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for the treatment of neurodegeneration.
Unmasking the X: EPAC2 shifts the fragile X landscape
BioWorld
Researchers at UCLA have shown that divergent neuronal signaling in fragile X mice converges on EPAC2, a druggable target whose inhibition restores circuit...
Recludix presents STAT1/3 inhibitors for dermatological diseases
BioWorld Science
Recludix Pharma Inc. recently presented data on their new STAT1/3 inhibitors REX-6553 and REX-6547 for treating dermatological inflammatory skin diseases.